<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836914</url>
  </required_header>
  <id_info>
    <org_study_id>101-04</org_study_id>
    <nct_id>NCT00836914</nct_id>
  </id_info>
  <brief_title>Study to Investigate Effects of CAL-101 in Subjects With Allergic Rhinitis Exposed to Allergen in an Environmental Chamber</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Period Crossover Study to Investigate the Safety of CAL-101 in Allergic Rhinitis Subjects and Effects on the Response to Environmental Chamber Allergen Challenge</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effect of CAL-101 in subjects with&#xD;
      allergic rhinitis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Phase I, randomized, double-blind crossover study of CAL-101, an oral inhibitor of&#xD;
      phosphatidylinositol 3-kinase (PI3K) delta, in patients with allergic rhinitis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the safety CAL-101 using adverse events, vital signs, clinical laboratory tests, spirometry and ECG</measure>
    <time_frame>Baseline to Day 35</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in total nasal symptom score</measure>
    <time_frame>Baseline to Day 35</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>CAL-101</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAL-101</intervention_name>
    <description>CAL-101 100mg capsules administered orally twice a day (BID) for 7 days</description>
    <arm_group_label>CAL-101</arm_group_label>
    <other_name>Idelalisib</other_name>
    <other_name>GS-1101</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules administered orally BID for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; or = 18 and &lt; or = 55 years&#xD;
&#xD;
          2. Has a history of seasonal allergic rhinitis for at least 2 years&#xD;
&#xD;
          3. Has sensitivity to grass pollen demonstrated by a positive response to skin prick&#xD;
             testing&#xD;
&#xD;
          4. Has a positive Radio Allergen Sorbent Test (&gt; or = class 2) for grass pollen during&#xD;
             the previous 12 months or at screening&#xD;
&#xD;
          5. Is otherwise healthy, that is, free from clinically significant illness or disease as&#xD;
             determined by medical history, physical examination and laboratory tests, including a&#xD;
             normal 12-lead electrocardiogram (ECG)&#xD;
&#xD;
          6. Has no conditions which would make the subject unlikely to be able to remain in the&#xD;
             allergen challenge chamber for 4 hours&#xD;
&#xD;
          7. Is available to complete all study procedures&#xD;
&#xD;
          8. Is able to provide written informed consent, including compliance with the&#xD;
             requirements and restrictions listed in the consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Is a female of childbearing potential (non-childbearing potential means documented&#xD;
             surgery resulting in infertility or postmenopausal with no menses for at least 1 year)&#xD;
&#xD;
          2. History of chronic nasal or upper respiratory tract symptoms or disorders other than&#xD;
             allergic rhinitis&#xD;
&#xD;
          3. History of nonallergic rhinitis, chronic sinusitis or severe asthma&#xD;
&#xD;
          4. Has a nasal condition likely to affect the outcome of the study, i.e. nasal septal&#xD;
             perforations, nasal polyps, sinus disease, chronic nasal obstruction, or other nasal&#xD;
             diseases&#xD;
&#xD;
          5. Is currently taking regular medication, whether prescribed or not, including&#xD;
             corticosteroids, vitamins, macrolides, anti-fungal agents and herbal remedies, e.g.&#xD;
             St. John's Wort. Paracetamol (&lt; or = 2g/day) and as needed use of short-acting&#xD;
             B2-agonists are allowed.&#xD;
&#xD;
          6. Has taken a prohibited medication within the specified interval prior to Visit 1:&#xD;
&#xD;
               -  Corticosteroids (depot, 90 days; systemic, 30 days; dermatologic 14 days)&#xD;
&#xD;
               -  Chromones (14 days)&#xD;
&#xD;
               -  Antihistamines (nasal and long-acting oral, 10 days; shorting-acting oral, 2&#xD;
                  days; ocular, 3 days)&#xD;
&#xD;
               -  Decongestants (3 days)&#xD;
&#xD;
               -  Leukotriene modifiers (10 days)&#xD;
&#xD;
               -  Anticholinergics (7 days)&#xD;
&#xD;
               -  Opthalmic nonsteroidal&#xD;
&#xD;
               -  anti-inflammatory drugs (3 days)&#xD;
&#xD;
               -  Nasal-ophthalmic wash solutions (12 hr)&#xD;
&#xD;
               -  Immunotherapy (12 hr)&#xD;
&#xD;
          7. Is currently being treated with a medication that induces or inhibits cytochrome P450&#xD;
             (CYP)3A&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Friedrich Horak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vienna Challenge Chamber</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vienna Challenge Chamber</name>
      <address>
        <city>Vienna</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <last_update_submitted>October 19, 2018</last_update_submitted>
  <last_update_submitted_qc>October 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic Rhinitis</keyword>
  <keyword>Allergy</keyword>
  <keyword>Phosphatidylinositol 3-kinase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at http://www.gilead.com/research/disclosure-and-transparency.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>18 months after study completion</ipd_time_frame>
    <ipd_access_criteria>A secured external environment with username, password, and RSA code.</ipd_access_criteria>
    <ipd_url>http://www.gilead.com/research/disclosure-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

